In a study led by UdeM's Andrés Finzi and colleagues in the U.S., the virus took four times longer to return in humanized mice whose antiretroviral therapy was stopped and who then got the cocktail.
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) and Yale University have succeeded in reducing the size of the HIV reservoir in humanized mice by using a “molecular can opener” and a combination of antibodies found in the blood of infected individuals.
In their study published in Cell Host & Microbe, the team of scientists, in collaboration with their colleagues at the University of Pennsylvania and Harvard Medical School, show that they were also able to significantly delay the return of the virus after stopping antiretroviral therapy in this animal model.
Humanized mice are generated from immunodeficient mice that don’t have their own immune system. They are transplanted with human immune cells and can be used to study diseases affecting the human immune system such as cancer, leukemia or HIV. Yale researchers developed a specific humanized mouse model with active “natural killer” (NK) cells, a type of immune cell, to study their role in HIV infection.
“With our cocktail of two antibodies naturally present in the plasma of HIV-infected people and a small ‘can opener’ molecule, we managed to ‘open up’ and stabilize a vulnerable form of the virus envelope,” said the study’s co-lead author Andrés Finzi, a researcher at the CRCHUM and professor at Université de Montréal. “The antibodies recognized the virus, had time to call the immune system’s ‘police’, the NK cells, and to get rid of the infected cells.”
To infect cells of the human immune system, HIV binds with its envelope to specific receptors on the surface of these cells, including one called CD4. This binding triggers changes in the shape of the virus envelope, its “key” to entry, and allows it to infect host cells.
In 2019, in an earlier study, a team led by Finzi and James Munro of Tufts University showed that small CD4-like molecules, designed and synthesized by the Amos Smith Group at U Pennsylvania, acted as “can openers” and were able to force the virus to open and expose vulnerable parts of its envelope.
“In our humanized mouse model developed at Yale and used to study HIV, we show that the cocktail not only limits viral replication, it also decreases the HIV reservoir by destroying infected cells,” said Yale infectious-diseases professor Priti Kumar, the study’s lead.
Successfully delaying the virus’s “rebound”
Throughout the course of antiretroviral therapy, HIV hides silently in reservoirs located in CD4+ T lymphocytes, the white blood cells that help activate the immune system against infections and fight microbes.
The existence of these hidden viral sanctuaries explains why antiretroviral therapy does not cure people with HIV and why they must remain on treatment for life to prevent the virus from “rebounding”.
“In humanized mice, we stopped antiretroviral therapy before administering our cocktail,” said Finzi. “The rebound of the virus occurred 46 days later as opposed to mice that did not get the cocktail, where rebound occurred within 10 days. Such efficiency in this animal model is really very promising.”
These findings open up new therapeutic avenues in the fight against this deadly virus, the researchers believe. According to the World Health Organization, 38 million people were living with HIV at the end of 2019.
About this study
“Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir,” by Jyothi K. Rajashekar, Jonathan Richard et al, was published May 20, 2021 in Cell Host & Microbe. The work was funded by the Canadian Institutes of Health Research, the U.S. National Institutes of Health (NIH), the Gilead Sciences Research Institute HIV Research Program, and the Foundation for AIDS Research (amfAR Research Consortium on HIV Eradication). Andrés Finzi holds the Canada Research Chair in Retroviral Entry.